pharma · Muscle-invasive bladder cancer · Unresectable intrahepatic cholangiocarcinoma
Ningbo Cancer Hospital
Ningbo Cancer Hospital is a pharma organization headquartered in CN. Primary therapeutic focus areas include Muscle-invasive bladder cancer, Unresectable intrahepatic cholangiocarcinoma, Head and neck squamous cell carci
Company details
- Status
- Public
- HQ
- CN
- Programs
- 120
- Drugs
- 183
- Patents
- 0
Afinitor 5 mg tablets, PLACEBO
Phase 3 · small molecule · Patients with high risk of relapse, ER+ and HER2- primary non-metastatic breast cancer who remain disease-free
Afinitor 5 mg tablets, PLACEBO for Patients with high risk of relapse, ER+ and HER2- primary non-metastatic breast cancer who remain disease-free is a Phase 3 program (small_molecule) at Ningbo Cancer Hospital with 1 ClinicalTrials.gov record(s).
Internal code UC-0140/1208
Full intelligence profile for this program is being prepared.
At a glance
- Sponsor
- Ningbo Cancer Hospital
- Phase
- Phase 3
- Modality
- small_molecule
- Indication
- Patients with high risk of relapse, ER+ and HER2- primary non-metastatic breast cancer who remain disease-free
- Status
- active
- Trials
- 1